Investing in the future of brain and mental health
INVESTMENT FOCUS
Neurotech & BCI
Digital Health
Precision Neuroscience
Platforms & Novel Therapeutics
Alternative Modalities
PURPOSE
We fund and support founders elevating brain and mental health through innovative neuroscience and frontier technologies. PsyMed founders align healing, responsibility, and profitability.
INVESTMENT FOCUS
We invest in frontier technologies transforming the mental and brain illness epidemic into a flourishing future.
ARTIFICIAL INTELLIGENCE
Advanced algorithms and machine learning to analyze vast data to enable early detection, accurate diagnosis, drug development and personalized treatment
NEUROTECH &
HUMAN AUGMENTATION
Direct connection of technical components with the brain and nervous system are addressing mental health disorders and neurological diseases
PRECISION NEUROSCIENCE
Paradigm of clinical care shifting from general approach for large populations to individual-based deep knowledge of clinical and biological characteristics
NEW MODALITIES
Genetic, RNA, cell, and any novel interventions that transcend conventional small molecules to transform brain health
HOLISTIC MEDICINE
Interconnection of biology, psychology, environment, and lifestyle, aiming to address root causes and promote overall well-being
NEUROMETABOLISM
Bidirectional relationship between metabolic processes and mental health, through diet, exercise, and gut microbiota can impact brain function.
PSYCHEDELIC MEDICINE
& NEW COMPOUNDS
Psychedelics and other novel compounds to treat brain and mental health conditions
DIGITAL HEALTH & THERAPEUTICS
Applications, wearables, and platforms that help patients treat, prevent, or manage a disease and enable personalized care
INVESTMENTS
MOTIF NEUROTECH
Minimally invasive bioelectronic solutions for TRD
SANMAI
Transcranial focused ultrasound for mental health
STEALTH MARKETPLACE
Marketplace for transformational mental health modalities
STEALTH NEUROTECH
Biohybrid brain-computer interfaces
STEALTH BIOTECH
Virtual organelle ML models
STEALTH BIOTECH
RNAi medicines to treat, delay, and prevent neurodegeneration
STEALTH BIOTECH
AI-guided polypharmacology engine
STEALTH HEALTHCARE
Integrated solution for cancer-specific behavioral health
STEALTH BIOTECH
Precision biologics for neuroinflammation
PEOPLE
Matias Serebrinsky
General Partner & Co-Founder
Matias is an investor, founder, and ecosystem builder. He previously led NVIDIA Inception North America, an accelerator for AI startups. Before that, he co-founded CookUnity, a foodtech company that delivered 23+ million meals last year. Matias is the co-host of Business Trip.
Greg Kubin
General Partner & Co-Founder
Greg is a community builder, investor, and founder. He is a co-host of Business Trip, a podcast exploring the future of mental health and wellness. Over 20 investments in mental health companies. Co-founded HelloSponsor, a SaaS platform (AngelPad '15). Ex-Morgan Stanley, Viacom.
Caitlin Ner
Director of Operations
Caitlin is an operator and community builder. Production lead of Business Trip. Previously led growth & ops at Cerebral, and alternative investing at BlackRock. Caitlin is ex-Harvard in Economics and Computer Science and a MSc Candidate in Applied Neuroscience at Kings College London.
Danny Carbonero PhD
Investment Associate
Danny is an investor and engineer. He previously worked at Breakout Ventures. He holds a PhD in Biomedical Engineering from Boston University, where he was an NIH F31 Fellow, with a research focus on computational neuroscience. While at BU, he helped lead Nucleate Boston.
Tucker Schwartz
Analyst
Sourcing, evaluating, and supporting companies innovating on the consumer side of brain & mental health.
Dina Burkitbayeva MBA/MS
Co-Founder
CEO at Freedom Biosciences, developing next-generation neuropsychiatric therapeutics. Co-founder at PsyMed.
Tim Gardner PhD
Venture Partner
Chair of Bioengineering at University of Oregon. Previously a founding member of Neuralink.
Brooks Leitner MD PhD
Venture Partner
CEO of a longevity company. Previously co-founder & CEO of EpiTET Therapeutics. VC experience at Canaan, Foresite, and BrightEdge.
Negin Mohktari PhD
Venture Partner
Biotech investor and oncology researcher. Previously a Partner at Bioluminescence Ventures and Senior Associate at Genoa Ventures.
John Krystal
MD
Advisor
Psychiatry. Translational Psychiatry, and Neuroscience at Yale University School of Medicine. Chief of Psychiatry at Yale-New Haven Hospital.
Graham Pechenik JD
Advisor
Legal/IP. Patent attorney. JD from NYU and BS in biochemistry & cognitive neuroscience from UCSD.
Alex Amen
PhD
Advisor
Gene and Cell Therapies. Biomedical scientist and Director of Asset Acquisition at BridgeBio. Postdoctoral training in the Doudna lab.
Chrystal Mavros PhD
Advisor
Microbiology. At Columbia University focused on gene therapy, gut-brain studies, next-gen sequencing, and postmortem brain analysis.
Jacob Robinson PhD
Advisor
Neurotech. CEO and Co-Founder of Motif Neurotech. Professor of Electrical and Computer Engineering at Rice University.
Building a company that’s elevating brain and mental health or looking to get involved as an investor?
SEND US AN EMAIL
